| 发明名称 |
(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol metabolites |
| 摘要 |
The present invention is directed to metabolites of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceutical compositions in the treatment of cancer.; |
| 申请公布号 |
US8778893(B2) |
申请公布日期 |
2014.07.15 |
| 申请号 |
US201013500365 |
申请日期 |
2010.10.04 |
| 申请人 |
Bristol-Myers Squibb Company |
发明人 |
Gong Jiachang;Christopher Lisa J.;Arora Vinod Kumar |
| 分类号 |
C07H15/26;C07D487/04 |
主分类号 |
C07H15/26 |
| 代理机构 |
|
代理人 |
Korsen Elliott |
| 主权项 |
1. A substantially pure compound which is a metabolite of the compound of formula (I)or a pharmaceutically acceptable salt form thereof, which metabolite is
1)or a pharmaceutically acceptable salt form thereof, or which metabolite is
2)or a pharmaceutically acceptable salt form thereof, or which metabolite is
3)or a pharmaceutically acceptable salt form thereof. |
| 地址 |
Princeton NJ US |
